DE69935078D1 - Eine mutante phospholamban moleküle und deren verwendung zur behandlung von herzkrankheiten und herzversagen - Google Patents

Eine mutante phospholamban moleküle und deren verwendung zur behandlung von herzkrankheiten und herzversagen

Info

Publication number
DE69935078D1
DE69935078D1 DE69935078T DE69935078T DE69935078D1 DE 69935078 D1 DE69935078 D1 DE 69935078D1 DE 69935078 T DE69935078 T DE 69935078T DE 69935078 T DE69935078 T DE 69935078T DE 69935078 D1 DE69935078 D1 DE 69935078D1
Authority
DE
Germany
Prior art keywords
heart
phospholamban
treatment
mutant
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69935078T
Other languages
English (en)
Other versions
DE69935078T2 (de
Inventor
Kenneth Chien
Wolfgang Dillman
Susanne Minamisawa
Huaping He
Masahiko Hoshijima
Markus Meyer
Christopher Scott
Yibin Wang
Gregg J Silverman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Application granted granted Critical
Publication of DE69935078D1 publication Critical patent/DE69935078D1/de
Publication of DE69935078T2 publication Critical patent/DE69935078T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69935078T 1998-11-02 1999-11-02 Eine mutante phospholamban moleküle und deren verwendung zur behandlung von herzkrankheiten und herzversagen Expired - Lifetime DE69935078T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10671898P 1998-11-02 1998-11-02
US106718P 1998-11-02
US14588399P 1999-07-27 1999-07-27
US145883P 1999-07-27
PCT/US1999/025692 WO2000025804A2 (en) 1998-11-02 1999-11-02 A method for inhibition of phospholamban activity for the treatment of cardiac disease and heart failure

Publications (2)

Publication Number Publication Date
DE69935078D1 true DE69935078D1 (de) 2007-03-22
DE69935078T2 DE69935078T2 (de) 2007-11-15

Family

ID=26803944

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69935078T Expired - Lifetime DE69935078T2 (de) 1998-11-02 1999-11-02 Eine mutante phospholamban moleküle und deren verwendung zur behandlung von herzkrankheiten und herzversagen

Country Status (8)

Country Link
EP (1) EP1126866B1 (de)
JP (2) JP2002528512A (de)
CN (1) CN1354671A (de)
AT (1) ATE353222T1 (de)
AU (1) AU1711100A (de)
CA (1) CA2349758A1 (de)
DE (1) DE69935078T2 (de)
WO (1) WO2000025804A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745416B2 (en) * 1995-04-11 2010-06-29 The Regents Of The University Of California Method for in vivo regulation of cardiac muscle contractility
DE10027777A1 (de) * 2000-06-07 2001-12-13 Otogene Ag Transfektionsverfahren
ATE423574T1 (de) * 2000-09-11 2009-03-15 Univ California Dominant-negativer plb mutant zur behandlung der herzerkrankungen
EP1421958A4 (de) * 2001-08-01 2008-10-08 Jms Co Ltd Blutreinigungsgerät zur erhöhung der reinigungseffizienz
US20050037420A1 (en) * 2001-09-14 2005-02-17 Mei-Yun Zhang Immunoglobulin having particular framework scaffold and methods of making and using
EP1693451B1 (de) * 2003-11-21 2011-11-09 Daiichi Sankyo Company, Limited Verfahren zur anzucht von myokardzellen
US7947645B2 (en) * 2004-09-02 2011-05-24 Cognosci, Inc. APO E analogs and methods for their use
US20060198825A1 (en) * 2005-03-03 2006-09-07 Kaemmerer William F Reagents, methods and systems to suppress phospholamban expression
GB0518027D0 (en) * 2005-09-05 2005-10-12 Birkeland Innovasjon As Compounds
EP2142571A4 (de) * 2007-05-02 2010-05-05 Intrexon Corp Pp1-liganden
US8221738B2 (en) 2008-02-19 2012-07-17 Celladon Corporation Method for enhanced uptake of viral vectors in the myocardium
WO2011005525A2 (en) 2009-06-22 2011-01-13 Health Research Inc. Prodrug anti-cancer therapy
CN103865945A (zh) * 2010-02-10 2014-06-18 中国人民解放军军事医学科学院放射与辐射医学研究所 Tat核心肽段在制备高效、可溶性表达的外源蛋白中的应用
WO2014007584A1 (en) * 2012-07-05 2014-01-09 Gwangju Institute Of Science And Technology Decoy peptides inhibiting protein phosphatase 1-mediated dephosphorylation of phospholamban
CN104193826B (zh) * 2014-09-17 2018-02-23 山东大学齐鲁医院 一种融合多肽及其在制备抗肿瘤药物中的应用
US11426441B2 (en) 2016-10-24 2022-08-30 Bethphagen Inc. Composition comprising protein phosphatase 1 inhibitory peptide for treating vascular diseases
CN106831956B (zh) * 2017-03-29 2019-11-08 华中科技大学同济医学院附属协和医院 一种抗肿瘤多肽mudp-21及其应用
CN115354043B (zh) * 2022-07-08 2023-12-08 南京大学 一种动物模型

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674980A (en) * 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
AU722840B2 (en) * 1996-03-30 2000-08-10 Medical Research Council Protein phosphatase-1 catalytic subunit interactions
FR2753722A1 (fr) * 1996-09-26 1998-03-27 Smithkline Beecham Lab Procede de detection de modulateurs de relaxation cardiaque et modulateurs ainsi obtenus
US5968959A (en) * 1997-12-12 1999-10-19 Orion Corporation Method for the prevention and treatment of stunned myocardium

Also Published As

Publication number Publication date
JP2008037870A (ja) 2008-02-21
DE69935078T2 (de) 2007-11-15
JP2002528512A (ja) 2002-09-03
WO2000025804A3 (en) 2000-10-05
CA2349758A1 (en) 2000-05-11
AU1711100A (en) 2000-05-22
CN1354671A (zh) 2002-06-19
EP1126866B1 (de) 2007-02-07
ATE353222T1 (de) 2007-02-15
EP1126866A2 (de) 2001-08-29
WO2000025804A2 (en) 2000-05-11
WO2000025804A9 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
DE69935078D1 (de) Eine mutante phospholamban moleküle und deren verwendung zur behandlung von herzkrankheiten und herzversagen
EE200200510A (et) POL1212 aminohappejärjestust kodeeriv DNA, seda sisaldav ekspressioonivektor, sea modifitseeritud VIII- tegur, sellel põhinev ravimkompositsioon ningmeetod sea modifitseeritud VIII-teguri aminohappejärjestust omava valgu valmistamiseks
PT1200105E (pt) Factor viii modificado
DE60032486D1 (de) Prion protein peptide und deren verwendung
GEP20043407B (en) Method of Inhibiting Amyloid Protein Aggregation and Imaging Amyloid Deposits Using Isoindoline Derivatives
CY1111120T1 (el) Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση
EA200101250A1 (ru) Предупреждение и терапия амилоидогенного заболевания
ES2170104T3 (es) Inhibidores de la produccion de proteinas de beta-amiloide.
ATE382364T1 (de) Von igf-bindungsprotein stammendes peptid
DE60218179D1 (de) Peptide zur behandlung von tumoren und anderen bedingungen die die entfernung oder zerstörung von zelle erfordern
HUP0300588A2 (hu) Rekombináns véralvadási faktorok előállítása humán sejtvonalakon
DK1521774T3 (da) Trunkerede Tau-proteiner
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
GEP20053423B (en) Method of Inhibiting Amyloid Protein Aggregation and Method for Imaging of Amyloid Deposits
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
DE69329656T2 (de) Methoden zur detektion und behandlung von individuen mit abnormalen hla-a2/tyrosinase-peptidantigenen exprimierenden zellen
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
DE50212280D1 (de) Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
ATE344325T1 (de) Neisseria lactoferrin-bindendes protein
DK1506295T3 (da) Muteiner af placental vækstfaktor type 1, fremstillingsfremgangsmåde og anvendelser deraf
EP3385276A1 (de) Aus clpb abgeleitete proteine und verwendungen davon
TR200103562T2 (tr) Amiloid proteini toplanmasını önleme ve amiloid birikintilerini görüntüleme yönteminde kullanım için rodanin türevleri
DE60143608D1 (de) Neueskollagen-ähnliches protein clac, dessen vorläufer und dafür kodierende gene

Legal Events

Date Code Title Description
8364 No opposition during term of opposition